Your browser doesn't support javascript.
loading
Proportional incidence of interval colorectal cancer in a large population-based faecal immunochemical test screening programme.
Mancini, Silvia; Bucchi, Lauro; Giuliani, Orietta; Ravaioli, Alessandra; Vattiato, Rosa; Baldacchini, Flavia; Ferretti, Stefano; Sassoli de Bianchi, Priscilla; Mezzetti, Francesca; Triossi, Omero; Serafini, Monica; Ricci, Enrico; Palazzi, Mauro; Imolesi, Claudia; Giovanardi, Mauro; Canuti, Debora; Voci, Claudio; Altini, Mattia; Falcini, Fabio.
Afiliação
  • Mancini S; Romagna Cancer Registry, Romagna Cancer Institute, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRST, IRCCS, Meldola, Italy.
  • Bucchi L; Romagna Cancer Registry, Romagna Cancer Institute, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRST, IRCCS, Meldola, Italy. Electronic address: lauro.bucchi@irst.emr.it.
  • Giuliani O; Romagna Cancer Registry, Romagna Cancer Institute, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRST, IRCCS, Meldola, Italy.
  • Ravaioli A; Romagna Cancer Registry, Romagna Cancer Institute, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRST, IRCCS, Meldola, Italy.
  • Vattiato R; Romagna Cancer Registry, Romagna Cancer Institute, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRST, IRCCS, Meldola, Italy.
  • Baldacchini F; Romagna Cancer Registry, Romagna Cancer Institute, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRST, IRCCS, Meldola, Italy.
  • Ferretti S; University of Ferrara and Local Health Authority, Ferrara, Italy.
  • Sassoli de Bianchi P; Department of Health, Emilia-Romagna Regional Administration, Bologna, Italy.
  • Mezzetti F; Department of Health, Emilia-Romagna Regional Administration, Bologna, Italy.
  • Triossi O; Cancer Screening Unit, Local Health Authority, Ravenna, Italy.
  • Serafini M; Cancer Screening Unit, Local Health Authority, Ravenna, Italy.
  • Ricci E; Department of Gastroenterology and Digestive Endoscopy, Local Health Authority, Morgagni-Pierantoni Hospital, Forlì, Italy.
  • Palazzi M; Cancer Screening Unit, Local Health Authority, Cesena, Italy.
  • Imolesi C; Cancer Screening Unit, Local Health Authority, Cesena, Italy.
  • Giovanardi M; Cancer Screening Unit, Local Health Authority, Rimini, Italy.
  • Canuti D; Cancer Screening Unit, Local Health Authority, Rimini, Italy.
  • Voci C; Servizio ICT, Tecnologie e Strutture Sanitarie, Department of Health, Emilia-Romagna Regional Administration, Bologna, Italy.
  • Altini M; Healthcare Administration, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRST, IRCCS, Meldola, Italy.
  • Falcini F; Romagna Cancer Registry, Romagna Cancer Institute, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRST, IRCCS, Meldola, Italy; Cancer Prevention Unit, Local Health Authority, Forlì, Italy.
Dig Liver Dis ; 52(4): 452-456, 2020 04.
Article em En | MEDLINE | ID: mdl-32165075
ABSTRACT

BACKGROUND:

The European guidelines for quality assurance in colorectal cancer (CRC) screening recommend that interval cancer rate be expressed as a proportion of background incidence rate.

AIM:

To determine the crude and adjusted proportional incidence of interval CRC in an Italian regional two-yearly faecal immunochemical test (FIT) screening programme.

METHODS:

The programme (year of implementation, 2005) is targeted at over 1,000,000 people aged 50-69 years. The test is a one-sample OC-Sensor (Eiken Chemical Co., Tokyo, Japan). The study covered one-third of the regional area. Excerpts of 434,295 eligible negative FIT records dated 2005-2012 from 193,193 subjects were retrieved from the regional CRC screening data warehouse. By 31 December 2013, the cohort accumulated 198,302 man-years and 235,370 woman-years. Interval CRCs were identified by record-linkage with the local population-based cancer registry. Their number was divided by the expected number, estimated with age-period-cohort models, to obtain the proportional incidence.

RESULTS:

The proportional incidence of interval CRC for men and women was, respectively, 0.06 (95% confidence interval (CI), 0.04-0.09) and 0.17 (95% CI, 0.13-0.23) in the first interval year, and 0.21 (95% CI, 0.16-0.26) and 0.28 (95% CI, 0.22-0.36) in the second year.

CONCLUSIONS:

The results were acceptable and in line with previous studies.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Detecção Precoce de Câncer / Sangue Oculto Tipo de estudo: Diagnostic_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Aged / Female / Humans / Male / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Detecção Precoce de Câncer / Sangue Oculto Tipo de estudo: Diagnostic_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Aged / Female / Humans / Male / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2020 Tipo de documento: Article